+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020

  • PDF Icon

    Report

  • 26 Pages
  • July 2020
  • Region: Global
  • GlobalData
  • ID: 5136766
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Coronavirus Disease 2019 (COVID-19) Impact on Immunology Trials - July 2020

Summary

Since the beginning of March 2020, clinical trial operations were most disrupted as a result of the COVID-19 pandemic. This report summarizes the impact on immunology patient, clinical trial logistics, and key opinion leader (KOL) insights on the long-term impact of the pandemic.

Scope

  • Global overview of changes to clinical practice and clinical trial logistics in H1 2020 in 8MM (US, 5EU, Japan, Canada)
  • Summary of primary research with Immunology Key Opinion Leaders
  • Forward-looking perspective of potential long-term ramifications of COVID pandemic

Reasons to Buy

  • Understand the impact of COVID-19 on immunology clinical trials
  • Obtain a snapshot of the regulatory guidance issued by the US FDA, EMA, and Health Canada
  • Understand the impact of COVID on continuity of care for immunology patients
  • Understand the impact of COVID on clinical trial logistics (including trial recruitment, trial conduct, and supply chain)
  • Understand the potential long-term impact of COVID on clinical trial conduct and clinical practice

Table of Contents

1 Immunology Trials Disrupted
1.1 Overview of Immunology Trials Disrupted
1.2 Regulatory Guidance Across the 8MM
2 KOL Insights: Continuity of Care
3 KOL Insights: Trial Logistics
3.1 Recruitment
3.2 Conduct in Isolation
3.3 Supply Chain
4 KOL Insights: Trials Looking Forward
4.1 Clinical Trials Disrupted Due to COVID
4.2 Immunology Clinical Trials Resumed
5 Appendix
5.1 Sources Used
5.2 About the Authors
5.3 Get in Touch